NL2014148B1 - Combination vaccine for camelids. - Google Patents

Combination vaccine for camelids. Download PDF

Info

Publication number
NL2014148B1
NL2014148B1 NL2014148A NL2014148A NL2014148B1 NL 2014148 B1 NL2014148 B1 NL 2014148B1 NL 2014148 A NL2014148 A NL 2014148A NL 2014148 A NL2014148 A NL 2014148A NL 2014148 B1 NL2014148 B1 NL 2014148B1
Authority
NL
Netherlands
Prior art keywords
mers
mva
virus
immunogenic
camelids
Prior art date
Application number
NL2014148A
Other languages
English (en)
Other versions
NL2014148A (en
Inventor
Leonardus Haagmans Bartholomeus
Dominicus Marcellinus Erasmus Osterhaus Albertus
Original Assignee
Univ Erasmus Med Ct Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Erasmus Med Ct Rotterdam filed Critical Univ Erasmus Med Ct Rotterdam
Priority to NL2014148A priority Critical patent/NL2014148B1/en
Priority to PCT/NL2016/050040 priority patent/WO2016114669A1/en
Publication of NL2014148A publication Critical patent/NL2014148A/en
Application granted granted Critical
Publication of NL2014148B1 publication Critical patent/NL2014148B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Claims (6)

1. Werkwijze voor het voorkomen van infectie met kamelenpokken en MERS coronavirus in kameelachtigen, waarin aan genoemde kameelachtigen een immunogene samenstelling omvattende het MVA virus als een vector omvattende een immunogeen element van het MERS coronavirus wordt toegediend.
2. Werkwijze volgens conclusie 1, waarin genoemde kameelachtige gekozen is uit de groep bestaande uit kameel, dromedaris, lama, alpaca, vucuna en guanaco.
3. Werkwijze volgens een der voorgaande conclusies, waarin het immunogene element van het MERS coronavirus het spike (S) eiwit is.
4. Werkwijze voor het voorkomen van verspreiding van het MERS coronavirus door het uitvoeren van een werkwijze volgens een der conclusies 1-3.
5. Werkwijze voor het verminderen van het risico op besmetting van mensen met MERS coronavirus door het uitvoeren van een werkwijze volgens een der conclusies 1 -3
6. Toepassing van een MVA virale vector waarin een immunogeen element van MERS coronavirus is ingebouwd voor het voorkomen van zowel kamelenpokken en MERS in kameelachtigen
NL2014148A 2015-01-16 2015-01-16 Combination vaccine for camelids. NL2014148B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NL2014148A NL2014148B1 (en) 2015-01-16 2015-01-16 Combination vaccine for camelids.
PCT/NL2016/050040 WO2016114669A1 (en) 2015-01-16 2016-01-18 Combination vaccine for camelids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2014148A NL2014148B1 (en) 2015-01-16 2015-01-16 Combination vaccine for camelids.

Publications (2)

Publication Number Publication Date
NL2014148A NL2014148A (en) 2016-09-26
NL2014148B1 true NL2014148B1 (en) 2017-01-05

Family

ID=55538570

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2014148A NL2014148B1 (en) 2015-01-16 2015-01-16 Combination vaccine for camelids.

Country Status (2)

Country Link
NL (1) NL2014148B1 (nl)
WO (1) WO2016114669A1 (nl)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO2001068820A1 (en) 2000-03-14 2001-09-20 Anton Mayr Altered strain of the modified vaccinia virus ankara (mva)
KR20150064104A (ko) 2012-09-23 2015-06-10 에라스무스 유니버시티 메디컬 센터 로테르담 사람 베타 코로나바이러스의 계통 c 및 이의 바이러스 수용체로서 n-말단 디펩티딜 펩티다아제의 확인
US9889194B2 (en) * 2013-03-01 2018-02-13 New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection

Also Published As

Publication number Publication date
WO2016114669A1 (en) 2016-07-21
NL2014148A (en) 2016-09-26

Similar Documents

Publication Publication Date Title
JP6130876B2 (ja) 複製欠損性組換えウイルスワクチン中の抗原に対する細胞傷害性ｔ細胞応答に有利である反復ワクチン接種と組み合わされた最適化初期−後期プロモーター
US7189536B2 (en) Modified vaccinia ankara virus variant
KR100571479B1 (ko) Hiv에 대한 폴리엔브백신으로서 재조합 백시니아벡터의 혼합물
EP2627774B1 (en) Recombinant modified vaccinia virus ankara (mva) influenza vaccine
EA011557B1 (ru) Конструкции нуклеиновых кислот
US20210393766A1 (en) Recombinant Modified Vaccinia Virus Ankara (MVA) Foot and Mouth Disease Virus (FMDV) Vaccine
CN113444156B (zh) 新型冠状病毒肺炎重组人5型腺病毒疫苗
CN102281897A (zh) 通过机械破坏表皮进行痘病毒载体的疫苗接种
CA2676809C (en) Immediate protection against pathogens via mva
WO2023077147A2 (en) T-cell vaccines for patients with reduced humoral immunity
NL2014148B1 (en) Combination vaccine for camelids.
US20230233670A1 (en) A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease
EP2155883A1 (en) Raccoon poxvirus expressing genes of feline antigens
US20120003263A1 (en) Recombinant raccoon pox virus vaccine against highly pathogenic avian influenza
CN113913393B (zh) 新型冠状病毒肺炎的重组新城疫病毒疫苗
US11013791B2 (en) NYVAC-based plasmodium malaria vaccine
DK2627774T3 (en) INFLUENZAVACCINE BASED ON RECOMBINANT MODIFIED VACCINIAVIRUS ANKARA (VAT)
EP2042604A1 (en) VV promoter driven overexpression of recombinant antigens
JP2024512103A (ja) ワクチンプラットフォームとしての高弱毒化複製可能組換えポックスウイルスおよびその利用方法
CN115040644A (zh) 新冠肺炎重组狂犬病病毒载体疫苗
CN113227360A (zh) 具有新型流感病毒来源的血凝素蛋白基因的DIs株来源的重组牛痘病毒
US20110177115A1 (en) Vaccination regimen

Legal Events

Date Code Title Description
MM Lapsed because of non-payment of the annual fee

Effective date: 20180201